NEW YORK, August 13, 2025 — Leads & Copy — Indaptus Therapeutics Inc. (Nasdaq: INDP) announced its financial results for the second quarter ended June 30, 2025, along with a corporate update. The clinical-stage biotechnology company focuses on innovative cancer and viral infection treatments.
CEO Jeffrey Meckler highlighted the dosing of the first patient in a Phase 1b/2 combination study evaluating Decoy20 with tislelizumab, a PD-1 checkpoint inhibitor. Preclinical studies suggested that Decoy20 enhances immune cell activation and works synergistically with PD-1 inhibitors for solid tumor regression.
Indaptus raised approximately $5.7 million in gross proceeds through convertible promissory notes and warrants, which were converted into common stock and pre-funded warrants in July. This financing is expected to bolster the company’s balance sheet and support clinical development.
Key highlights include the first patient dosed in the Decoy20 and tislelizumab combination study, $5.7 million raised via private placement, and Dr. Michael Newman’s appointment as chair and expert speaker at the Cytokine-Based Drug Development Summit.
Second-quarter financial results revealed research and development expenses of approximately $2.2 million, up from $1.7 million in 2024, due to the Phase 1 study. General and administrative expenses were approximately $2.3 million, slightly down from $2.4 million in 2024.
The loss per share was approximately $9.09, compared to $13.16 in the previous year. As of June 30, 2025, the company had approximately $6.2 million in cash and cash equivalents.
Indaptus expects to share initial combination trial data later this year and remains focused on executing its clinical strategy.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com
Source: Indaptus Therapeutics, Inc.
